Taysha Gene Therapies, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Taysha Gene Therapies, Inc. TSHA.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2026
The Dallas Texas-based company is expected to report revenue of $618.18 thousand, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Taysha Gene Therapies, Inc. is for a loss of 13 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Taysha Gene Therapies, Inc. is $12.00, about 174.6% above its last closing price of $4.37
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.12 | -0.12 | -0.14 | Missed | -20.1 |
Mar. 31 2026 | -0.10 | -0.10 | -0.12 | Missed | -22.9 |
Dec. 31 2025 | -0.08 | -0.10 | -0.08 | Beat | 16.8 |
Sep. 30 2025 | -0.09 | -0.09 | -0.09 | Met | -2 |
Jun. 30 2025 | -0.08 | -0.08 | -0.09 | Missed | -11.2 |
Mar. 31 2025 | -0.09 | -0.09 | -0.08 | Beat | 13.6 |
Dec. 31 2024 | -0.08 | -0.08 | -0.07 | Beat | 15.7 |
Sep. 30 2024 | -0.10 | -0.09 | -0.10 | Missed | -8 |
This summary was machine generated November 10 at 13:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)